Enliven Therapeutics (ELVN) Prepaid Assets (2019 - 2026)
Enliven Therapeutics (ELVN) posted Prepaid Assets of $10.7 million for Q1 2026, down 12.41% sequentially from $12.3 million in Q4 2025, and up 125.4% YoY from $4.8 million in Q1 2025.
Enliven Therapeutics (ELVN) Prepaid Assets (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Prepaid Assets for 8 years, with the latest figure at $10.7 million in Q1 2026.
- Quarterly Prepaid Assets rose 125.4% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 125.4% YoY) and the FY2025 annual result came in at $12.3 million, up 164.56% from the prior year.
- Prepaid Assets retreated to $10.7 million in Q1 2026 per ELVN's latest filing, from $12.3 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $12.3 million in Q4 2025 and troughed at $2.2 million in Q4 2022.
- A 5-year average of $5.5 million and a median of $5.1 million in 2025 frame the typical range for Prepaid Assets.
- The widest YoY moves for Prepaid Assets: up 164.56% in 2025, down 28.28% in 2025.
- Over 5 years, Prepaid Assets stood at $2.2 million in 2022, then jumped by 33.02% to $2.9 million in 2023, then surged by 57.1% to $4.6 million in 2024, then jumped by 164.56% to $12.3 million in 2025, then slipped by 12.41% to $10.7 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $10.7 million, $12.3 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.18 Mn |
| Mar 31, 2026 | 10.74 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | 5.12 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Dec 31, 2024 | 4.63 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 5.68 Mn |
| Mar 31, 2024 | 6.64 Mn |
| Dec 31, 2023 | 2.95 Mn |
| Sep 30, 2023 | 5.13 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 5.90 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 3.92 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 2.42 Mn |
| Sep 30, 2021 | 3.16 Mn |